Golden Shower Tree (Cassia fistula L.): A Comprehensive Reference
1. Identity, Nomenclature, and Botanical Description
Scientific and Common Names
Cassia fistula L. is also known as golden shower, purging cassia, Indian laburnum, kani konna, and pudding-pipe tree; it is a flowering plant in the family Fabaceae. Within the subfamily Caesalpinioideae, it has historically also been classified under the family Caesalpiniaceae, a designation still frequently found in the pharmacological literature. It is commonly known in Ayurveda as Aragvadha or Indian Laburnum, and is a medium-sized deciduous tree belonging to the Leguminosae family. In Hindi it is called Amaltas; in Tamil, Konnei; in Bengali, Sonali or Bandor lathi; and in Persian/Unani medicine, Folus or Khiar shanbar. In Ayurvedic medicine, the golden shower tree is known as aragvadha, meaning "disease killer."
Geographic Origin and Distribution
The species is native to the Indian subcontinent and adjacent regions of Southeast Asia. It is aboriginal to India and Sri Lanka, and has diffused into various countries, including Mexico, China, Mauritius, East Africa, South Africa, and the West Indies. It is the official state flower of Kerala and Delhi in India, as well as the national tree and flower of Thailand.
Morphological Features
The golden shower tree is a medium-sized tree growing to 10–20 m tall with fast growth. The leaves are deciduous, 15–60 cm long, and pinnate with three to eight pairs of leaflets, each leaflet 7–21 cm long and 4–9 cm broad. Five-petaled, bright yellow flowers bloom in 8–18 inch pendulous terminal racemes which cover the tree with profuse bloom. Flowers are lightly scented. Pods emerge green but mature to black, remaining on the tree until the following year; the sticky brown pulp inside the pods has been used in herbal medicines.
Common Preparations and Forms
Traditionally, the plant is used as an infusion, decoction, or powder, either alone or in combination with other medicinal plants. Commercially available preparations include standardized dried fruit pulp extracts, churna (powder), kwath (decoction), and emulsified liquid preparations used in clinical settings. Every part of this plant, including the bark, leaves, flowers, fruit pulp, and seeds, has been utilized to treat a wide range of diseases.
2. Traditional and Historical Use
Ayurveda (Indian subcontinent, 1st millennium CE onward)
Cassia fistula is an important medicinal plant used in many traditional medicinal systems, including Ayurveda and Chinese Traditional Medicine. It serves as a medicinally significant tree used in conventional practices of medicine such as Ayurveda, Unani, and Siddha (AYUSH). In Ayurveda, the plant features prominently in classical texts. According to Ayurveda, the leaves and seeds are acrid, laxative, antiperiodic, anthelmintic, ophthalmic, liver tonic, cardiotonic, and expectorant. It is considered the best drug among mild purgatives and is regarded as suitable for children, elderly, wounded, emaciated, and sensitive people.
The fruit pulp holds the most central place in Ayurvedic therapeutics. The pulp is considered a safe purgative, and is recommended for children and pregnant women; it is given in disorders of the liver and in biliousness, and acts as a tonic; it is also applied in gout and rheumatism. The powder or decoction of the bark is administered in leprosy, jaundice, syphilis, and heart diseases.
The plant appears in a variety of classical Ayurvedic compound formulations. Aragwadhadi Kashayam, an herbal decoction with Aragvadha as its main ingredient, is used in vomiting, skin diseases, pruritus, and non-healing wounds. Aragwadharishtha and Aragwadhavaleha are also used in Ayurvedic therapeutics to treat various disease conditions. The plant constitutes the Ayurvedic preparation "Dadrughan-vati," used for ringworm and leucoderma. Chakramardha tailamu, a compound Ayurvedic oil of this herb, is beneficial in eczema, ringworm, and other skin diseases.
Unani Medicine
In traditional medicine, Cassia fistula is one of the most commonly used plants in Unani and Ayurvedic medicines, and has been described to be useful against skin diseases, liver troubles, and tuberculous glands; its use in the treatment of haematemesis, pruritus, leucoderma, and diabetes has been suggested. In the Unani system of medicine, Cassia fistula bark decoction is used to treat long-term illnesses such as leprosy, syphilis, menstrual problems, and heart problems. During the medieval period, Avicenna (Ibn Sina) documented the external use of cassia pulp for joint conditions; he noted that "purging cassia is painted on gout and painful joints."
Traditional Iranian/Persian Medicine
In Persian medicine, Cassia fistula, called "Folus" or "Khiar shanbar," has been known as a safe and effective laxative for more than ten centuries. It was classified in Traditional Iranian Medicine (TIM) texts as a gentle, mucilaginous laxative appropriate for use in children.
Traditional Thai Medicine and Southeast Asia
In traditional medicine in Thailand, the ripe fruits are used as a laxative medicine. The tree's broad cultural significance in Thailand is reflected in its status as the national tree and flower.
Africa, the Caribbean, and Other Regions
Ghana natives used the fruit pulp as a purgative. In the Far East, the uncooked pulp was used as a popular remedy for constipation, and a decoction of the root bark was used for cleaning wounds. In Papua New Guinea, bark-scrapings and leaf sap are employed to heal broken bones and topical ulcers. The TRAMIL network, which documents and evaluates Caribbean plant medicine, records the use of fruit pulp decoctions or macerations for constipation and young leaf decoctions for inflammation in the Caribbean region.
In the broader ethnobotanical record: the leaves have been used for erysipelas, malaria, rheumatism, and ulcers; the buds for biliousness, constipation, fever, leprosy, and skin disease; and the fruit for abdominal pain, constipation, fever, heart disease, and leprosy.
3. Key Phytochemical Constituents
Overview of Chemical Classes
Cassia fistula has been reported to contain important classes of phytoconstituents including anthraquinone glycosides, cardiac glycosides, phenolic compounds, carbohydrates, protein, fats, alkaloids, tannins, saponins, steroids, terpenoids, phlobatannins, linoleic acid, oleic acid, stearic acid, rhein glycosides, fistulic acids, sennosides A and B, anthraquinones, flavonoid-3-ol derivatives, ceryl alcohol, kaempferol, bianthraquinone glycosides, fistulin, essential oils, volatile components, phytol (16.1%), 2-hexadecanone (12%), and 4-hydroxybenzoic acid hydrate.
Constituent Distribution by Plant Part
Each anatomical part of the tree has been found to contain a distinct phytochemical profile:
- Fruit pulp: The fruit contains glycosides including sennosides A and B, anthraquinone, tannin, oxyanthraquinone, volatile oil, ceryl alcohol, kaempferol, rhein, and fistulin, a bianthraquinone glycoside. The pulp of C. fistula fruit contains carbohydrates (26.3%), arginine, protein (19.9%), leucine, and flavonoid-3-ol derivatives.
- Leaves: The leaf contents include oxalic acid, pectin, tannin, barbaloin, aloin, sennosides A and B, rhein, glucoside, formic acid, butyric acid, and their ethyl esters.
- Stem bark: The stem bark contains lupeol, hexacosanol, tannins, and β-sitosterol. Lupeol, β-sitosterol, hexacosanol, and several complex flavonol and xanthone glycosides are also present in the stem bark.
- Flowers: Anthraquinone, hentriacontanoic acid, heptacosanoic acid, nonacosanoic acid, and triacontanoic acid are abundant in flowers.
- Pods: The pods contain astringent matter, fistulic acids, gluten matter, and kaempferol.
- Seeds: Epiafzelechin, (+)-catechin, dihydrokaempferol, kaempferol, and 1,8-dihydroxy-3-methylanthraquinone are all found in seeds.
- Roots: Phlobaphenes, oxyanthraquinone, tannins, and rhamnetin-3-O-gentiobioside are abundant in roots.
An important compound isolated from the roots is rhamnetin 3-O-gentiobioside, and from the fruits, the isoflavone biochanin A. Purified rhamnetin 3-O-gentiobioside (from roots), sennosides A and B (from leaves), fistulin and kaempferol (from flowers), isoflavone biochanin A (from fruits), and three new compounds designated cassioates D, E, and F (from the whole plant) have been previously isolated from C. fistula.
Key Bioactive Compounds and Their Mechanistic Significance
The plant exhibits a broad spectrum of therapeutic properties, including antioxidant, anti-inflammatory, antidiabetic, hepatoprotective, antimicrobial, and anticancer activities, largely attributed to key phytoconstituents such as rhein, emodin, quercetin, and kaempferol.
- Anthraquinones (rhein, emodin, sennosides A and B, fistulin): These are the primary active compounds behind the plant's laxative action. The fruit pod contains seeds surrounded by sweet, dark pulp primarily used in the management of constipation due to its anthraquinone and high mucilage content. These compounds are metabolized by gut bacteria into active agents that stimulate intestinal peristalsis and increase water and electrolyte secretion, softening stool and easing bowel movements.
- Flavonoids (kaempferol, quercetin, catechin): Extracts of C. fistula—particularly from the fruit pulp and flowers—have demonstrated potent antioxidant effects in various in vitro models, including DPPH, ABTS, FRAP, and nitric oxide scavenging assays; these effects are attributed to polyphenolic compounds such as quercetin, kaempferol, and rhein, which are known to donate hydrogen atoms and interrupt oxidative chain reactions.
- Anti-inflammatory mechanisms: Ethanolic extracts of C. fistula pods and pulp have shown anti-inflammatory activity in acute and chronic models; collagen-induced arthritic rats treated with fruit extract exhibited reduced paw edema and pro-inflammatory cytokines (TNF-α, IL-6, IL-17), an effect mediated via inhibition of NF-κB and COX-2.
- Tannins and proanthocyanidins: Total phenolic content, total flavonoids, condensed tannin, and saponins have been quantified in extracts, with values of 13.07 mg GAE/g, 5.24 mg QE/g, 4.01 mg/g, and 27.55%, respectively.
- Polysaccharides: A polysaccharide extracted from Cassia fistula mature fruit pulp has been investigated for effects on probiotic strains including L. casei, L. rhamnosus, E. coli Nissle 1917, and E. faecalis; the molecular weight of this polysaccharide was approximately 8.707 × 10⁵ Da.
4. Pharmacological Activities and Scientific Evidence
4.1 Laxative and Gastrointestinal Effects
Evidence level: Moderate — supported by multiple randomized controlled trials in children.
The laxative effect of C. fistula fruit pulp is the most clinically studied property and the one with the strongest human evidence. Two randomized clinical trials conducted by the same research group at Amirkola Children's Hospital, Iran, provide the primary clinical data.
Study 1 (vs. Mineral Oil): A randomized clinical trial was carried out on 81 children (age range 4–13 years) with functional constipation according to Rome III criteria; they received cassia fistula emulsion (CFE) or mineral oil randomly for three weeks. 41 children were randomly assigned to receive CFE and 40 received mineral oil; after three weeks, 84% of children in the CFE group and 50% in the mineral oil group (p = 0.002) exited from the criteria of functional constipation. The frequency of defecation in the CFE group improved from 1.7 per week before the study to 10.6 per week at the third week, while in the mineral oil group it changed from 2 to 6.1 (p < 0.001); the severity of pain during defecation and consistency of stool improved significantly better in the CFE group than the mineral oil group (p < 0.05). Anal leakage of oily material occurred as an important complication in the mineral oil group, while children in the CFE group did not report this; drug compliance was not significantly different between the two groups, and neither CFE nor mineral oil caused clinically significant side effects.
Study 2 (vs. Polyethylene Glycol 4000): A randomized, open-label, prospective, controlled, parallel-group clinical trial was carried out on 109 children (M/F: 63/46; mean age ± SD: 59.7 ± 28.8 months) at Amirkola Children's Hospital; the inclusion criteria were based on diagnosis of functional constipation according to Rome III criteria with age range 2–15 years; they received CFE or PEG randomly for four weeks.
The TRAMIL Caribbean plant medicine network classifies the oral use of fruit pulp or decoctions for constipation as a recommended use (REC), based on significant traditional use documentation and published scientific information. The use of fruit pulp and fresh leaves in decoction taken orally for constipation is classified as REC based on significant traditional use documented in TRAMIL surveys and the scientific information published.
A more recent clinical study registered in the Indian Clinical Trials Registry (CTRI/2024/08/072838) evaluated a standardized extract of C. fistula over 14 days compared to senna extract. Clinical studies have confirmed the laxative properties of C. fistula fruit pulp, often comparing it to conventional treatments.
Limitations: All published RCTs have been conducted in pediatric populations by a single research group in Iran. No large, multi-center, blinded RCTs have been conducted in adults. Long-term efficacy and safety data are lacking.
4.2 Antidiabetic / Hypoglycemic Activity
Evidence level: Preliminary — animal and in vitro data only; no published human clinical trials.
The antidiabetic potential of C. fistula has been explored in alloxan- and streptozotocin-induced diabetic rat models; aqueous and alcoholic extracts of the fruit pulp significantly reduced fasting blood glucose levels. The leaves of C. fistula, specifically an ethyl acetate extract, possess significant hypoglycemic activity in alloxan-induced diabetic rats. Several studies suggest that Cassia fistula possesses antidiabetic effects, attributed to its bioactive components including flavonoids, anthraquinones, and saponins; these compounds are believed to influence glucose metabolism, improve insulin sensitivity, and reduce oxidative stress; experimental studies, primarily in animal models, have demonstrated that extracts can lower blood glucose levels, enhance antioxidant defense systems, and protect pancreatic β-cells from damage. However, despite promising preclinical evidence, clinical trials on its safety and efficacy in humans remain limited.
4.3 Antioxidant Activity
Evidence level: Established in vitro; not yet validated in human clinical trials.
Extracts of C. fistula—particularly from the fruit pulp and flowers—have demonstrated potent antioxidant effects in various in vitro models, including DPPH, ABTS, FRAP, and nitric oxide scavenging assays. DPPH and FRAP activity of fruit extract have been quantified at 63.30 μg/mL and 15.02 nmol/g, respectively. These effects are attributed to the high phenolic and flavonoid content of the plant, particularly quercetin, kaempferol, and rhein.
4.4 Hepatoprotective Activity
Evidence level: Preclinical (animal models); no human clinical trials published.
The results of one study showed that the ethanolic leaf extract (ELE) of Cassia fistula exhibits good hepatoprotective effect against diethylnitrosamine (DEN)-induced hepatotoxicity in ethanol-pretreated rats; ELE exhibited significant anti-lipid peroxidative, membrane-stabilizing, and antioxidant activities. The leaves of C. fistula showed significant hepatoprotective advantages by reducing the blood levels of bilirubin, transaminase, and alkaline phosphatase, comparable to a normal hepatoprotective medication, in animal studies. Seeds of the plant have also been studied for protection against paracetamol-induced hepatic injury in rats.
4.5 Anti-inflammatory Activity
Evidence level: Preclinical (in vitro and animal models); no human clinical trials published.
One study evaluated the anti-inflammatory activity of aqueous and alcoholic extracts of C. fistula bark in sub-acute models of inflammation; results confirmed that extracts showed significant anti-inflammatory effect in both air pouch granuloma and cotton pellet granuloma models. The mechanistic basis involves inhibition of NF-κB and COX-2 pathways as described in preclinical arthritic models.
4.6 Antimicrobial and Antifungal Activity
Evidence level: Preclinical — in vitro studies; no published human clinical trials.
Extracts from various parts of C. fistula have displayed broad-spectrum antibacterial and antifungal activity. Activity has been documented against organisms including E. coli, Staphylococcus aureus, and Candida species. Antifungal activity against fluconazole-resistant Candida has been reported in vitro. Particularly noteworthy is the antibacterial action against a wide range of bacterial and fungal infections. All evidence for antimicrobial efficacy remains at the in vitro or animal-model stage, and clinical utility in treating human infections has not been established through trials.
4.7 Antitumor / Anticancer Activity
Evidence level: Preliminary — in vitro and animal studies only; no human clinical trials.
Preclinical studies have examined the antitumor properties of C. fistula extracts in cell lines and animal models including Ehrlich ascites carcinoma. These studies remain at an early investigational stage. Modern pharmacological studies have validated multiple therapeutic properties including hepatoprotective, anticancer, antipyretic, anti-inflammatory, antimicrobial, antifertility, antitussive, antiepileptic, antiulcer, and antioxidant potential. No evidence from human clinical trials has been published.
4.8 Hypolipidemic Activity
Evidence level: Animal data; no human clinical trials.
Treatment with C. fistula extract at different doses has significantly restored levels of serum lipid, MDA, and enzyme activities in the liver and heart of hyperlipidemic mice; Oil Red O staining of visceral adipose tissue showed marked reduction of lipid accumulation in adipocytes, and administration at 500 mg/kg showed remarkable (p < 0.001) hypolipidemic and antioxidant effects in high-fat-diet-fed mice.
4.9 Prebiotic Potential
Evidence level: In vitro only.
A polysaccharide extracted from Cassia fistula mature fruit pulp has been investigated for its effects on probiotic strains including L. casei, L. rhamnosus, E. coli Nissle 1917, and E. faecalis, with these strains compared for their growth behavior in culture media supplemented with different concentrations of the polysaccharide. Clinical translation of this in vitro finding has not yet occurred.
5. Body Systems and Health Areas Associated with Cassia fistula
- Gastrointestinal system: Laxative, purgative, antiulcer, and carminative activity; the most evidence-supported area of clinical use.
- Hepatobiliary system: Hepatoprotective activity is traditionally claimed and has been demonstrated preclinically.
- Integumentary (skin) system: Bark paste and leaf preparations have been used for ringworm, eczema, leucoderma, pruritus, and wound healing; these uses are supported by in vitro antimicrobial and anti-inflammatory data.
- Metabolic/endocrine system: Antidiabetic and hypolipidemic effects in animal models; no confirmed human evidence.
- Immune and inflammatory system: Anti-inflammatory and antioxidant mechanisms well-documented in vitro and in animal studies.
- Reproductive system: Antifertility effects documented in animal studies (see Safety section).
- Respiratory system: Antitussive properties are traditionally attributed to the plant, though scientific validation is limited.
6. Dosage Forms and Reported Dosages
Dosages reported in the literature span traditional Ayurvedic texts, ethnobotanical surveys, and the published clinical trial protocols. The following represent those recorded in source materials:
- Fruit pulp (fresh or as powder — Phala majja/churna): Classical Ayurvedic texts indicate phala majja (fruit pulp) at 10–20 g. Approximately four grams of the pulp is taken with an equal quantity of sugar or tamarind; as a purgative, 30 to 60 grams are required, but this quantity may cause colic, nausea, and flatulence.
- Seed powder (Bija churna): Seed powder (Bija churna) at 3–6 g.
- Root bark decoction (Mula Twak Kwatha): Root bark decoction at 10–15 ml.
- Flower juice (Pushpa Swarasa): Flower juice at 5–10 ml.
- Bark decoction (traditional preparation): 15–20 grams of stem bark collected, added to 2 cups of water, boiled, and reduced to half a cup, then filtered.
- Root bark decoction (folklore): 50–100 ml.
- Flowers (direct): 5–10 g.
- Constipation — traditional maceration (TRAMIL): 20–40 grams of fruit pulp prepared as a decoction or aqueous maceration; for maceration, add the pulp to 2 cups (½ litre) of boiled water, leave to rest for 12 hours, and drink 1 cup on an empty stomach in the morning.
- Decoction for inflammation (TRAMIL): 30 grams of young leaves in 1 litre of water, boiled for 5 minutes; cool and drink 1 cup 3 times a day.
- Clinical trial (pediatric constipation, Iran): Every 1 ml of the clinical emulsion contained 0.1 g of dried pulp of fruits of Cassia fistula.
- Leaf decoction for worm infestation (Ayurvedic practice): 20–30 grams of leaves are used to make a decoction or fresh juice; this is given on an empty stomach at a dose of 20 ml in children and 40 ml in adults.
7. Safety Considerations
General Acute Toxicology
In a study investigating acute oral toxicity of C. fistula seeds extract in mice, oral administration of crude extract at the highest tested dose of 5000 mg/kg resulted in no mortalities or evidence of adverse effects; throughout 14 days of treatment there were no changes in behavioural pattern, clinical sign, or body weight; no significant elevations were observed in biochemical analysis of blood serum; and histopathological examination revealed normal architecture and no significant adverse effects on the kidney, heart, liver, lung, or spleen.
In a separate study examining both acute and sub-acute oral toxicity of ethanol extract of C. fistula fruit in male Wistar rats, a single administration of the extract up to a dose of 5000 mg/kg did not induce mortality; the LD₅₀ was estimated as higher than 5000 mg/kg; the oral doses of C. fistula fruit extract were concluded to be safe as they did not exhibit any lethality or adverse effects in the acute and sub-acute toxicity studies in male rats. Chronic toxicity, mutagenicity, and carcinogenicity evaluations should be performed to have a better understanding of the plant's safety profile.
Gastrointestinal Adverse Effects at Higher Doses
As a purgative, 30 to 60 grams of fruit pulp may be required, but this quantity may cause colic, nausea, and flatulence. Overdoses of leaves, bark, and bark may cause vomiting, nausea, abdominal pain, and cramps. The clinical RCT in children reported that CFE and mineral oil did not cause clinically significant side effects at therapeutic emulsion doses.
Antifertility and Reproductive Concerns
This is a critical and source-verified safety concern. Oral administration of aqueous extract of seeds of Cassia fistula to mated female rats from day 1–5 of pregnancy at doses of 100 and 200 mg/kg body weight resulted in 57.14% and 71.43% prevention of pregnancy, respectively, whereas 100% pregnancy inhibition was noted at 500 mg/kg body weight. In uterine bioassay testing in immature bilaterally ovariectomized female rats, aqueous extract of seeds at 100 mg/kg body weight increased uterine wet weight (p < 0.05) and luminal epithelial cell height (p < 0.001), suggesting mild estrogenic activity of the extract. When the extract was administered conjointly with estradiol valerate (0.1 mg/kg body weight), it significantly (p < 0.001) prevented the estrogen-induced uterotrophic effect, indicating antiestrogenic nature of the extract in the presence of a strong estrogen. These findings are in animal models; no direct human reproductive safety data are available, but the results indicate that seed preparations in particular warrant caution during pregnancy and in those wishing to conceive.
Need for Further Safety Characterization
Although existing studies confirm its therapeutic potential, additional standardization and clinical trials are necessary for the advancement of modern pharmaceutical applications. Existing studies confirm therapeutic potential; however, additional standardization and clinical trials are necessary. No pharmacokinetic herb-drug interaction studies specific to C. fistula in humans have been published. Given that the plant contains anthraquinone glycosides structurally related to senna sennosides, potential interactions with drugs that affect electrolyte balance or gastrointestinal motility (e.g., cardiac glycosides, diuretics) should be considered in clinical contexts, as is standard for anthraquinone-containing botanical laxatives.
Pollen Allergenicity
Biochemical analysis of pollen grains has shown a protein composition of 12% with appreciable amounts of free amino acids such as phenylalanine, methionine, glutamic acid, and proline, suggesting potential allergenicity of pollen for sensitive individuals, though systematic allergological studies in humans have not been identified.
8. Overall Evidence Assessment
Cassia fistula is a medicinally valuable plant with a rich history of traditional applications, supported by modern pharmacological data; the plant's diverse bioactive compounds and documented therapeutic potential make it a promising candidate for the development of novel plant-based drugs. The strongest and most clinically verified use is as a mild laxative for pediatric functional constipation, supported by at least two published randomized controlled trials. All other proposed therapeutic uses — including antidiabetic, antimicrobial, hepatoprotective, anti-inflammatory, antitumor, and hypolipidemic effects — rest primarily on in vitro and animal-model evidence, with no published confirmatory human clinical trials. Additional standardization and clinical trials are necessary for the advancement of modern pharmaceutical applications.
References
Go back